The GLP-1 revolution has outpaced the behavioural science
Why digital health platforms may now be running the largest behavioural experiment in obesity care

GLP-1 medications have transformed the treatment landscape for obesity.
In a remarkably short period of time, pharmacological therapies such as semaglutide and tirzepatide have demonstrated levels of weight loss that were previously difficult to achieve outside of bariatric surgery. Demand has surged globally as both clinicians and patients recognise the potential of these treatments.
But an important detail is often overlooked in the public conversation around these medications.
In the clinical trials that led to their approval, GLP-1 therapies were almost never studied in isolation. They were typically delivered alongside structured lifestyle and behavioural interventions.
That was the treatment model.
Medication plus behavioural support.
Yet despite the rapid growth of pharmacological treatments for obesity, there is a surprising gap in the evidence base. We still have relatively limited high quality evidence about the most effective behavioural interventions to combine with these medications.
In other words, drug innovation has moved faster than the behavioural science.
A new real world laboratory
This creates a fascinating and important situation.
Digital health platforms delivering GLP-1 treatments are now operating at a scale that was rarely possible in traditional clinical research.
Hundreds of thousands of patients are interacting with these services.
Millions of digital touchpoints are being generated across patient journeys.
Within those interactions sit a wide range of behavioural signals:
• how patients respond to early side effects
• what happens during plateau periods
• when motivation drops
• what helps patients stay engaged long term
• how patients transition into long term maintenance
These are not purely clinical questions.
They are behavioural questions.
And the answers are embedded within the real world data generated by digital care platforms.
Obesity is a chronic disease
Another key point emphasised in the latest guidance is that obesity should be understood as a chronic disease requiring sustained management rather than a short term intervention.
This has important implications for how treatment systems are designed.
Pharmacotherapy may initiate weight loss, but long term outcomes depend heavily on behavioural factors such as adherence, nutrition, physical activity, and psychological support.
Digital health platforms therefore face a challenge that is partly clinical but deeply behavioural.
How do you design systems that support patients not just for weeks or months, but potentially for years?
Increasingly, the answer involves combining clinical care with behavioural science and AI enabled support systems that can respond to patients at scale.
From product data to behavioural insight
At the same time, many organisations now hold large volumes of patient interaction data but have limited ways of translating that information into meaningful behavioural insight.
The opportunity is significant.
If digital health platforms are effectively running one of the largest real world behavioural experiments in obesity care, the next question becomes whether we are learning from it.
At Sacher AI, much of our work sits at the intersection of industry and research.
Alongside building and evaluating AI systems for healthcare, our team conducts applied behavioural and clinical research designed to turn real world platform data into actionable insight. This includes identifying behavioural patterns in patient journeys, testing intervention strategies, and generating credible evidence that can inform both product development and clinical practice.
Because the next phase of innovation in obesity care may not come solely from new medications.
It may come from understanding behaviour better.
Related blog updates




